The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 28613895 |
66 |
A Highly Selective Hydantoin Inhibitor of Aggrecanase-1 and Aggrecanase-2 with a Low Projected Human Dose. |
Eli Lilly |
| 28274635 |
381 |
Identification of novel TACE inhibitors compatible with topical application. |
Nestl� |
| 27914947 |
11 |
Synthesis and binding monitoring of a new nanomolar PAMAM-based matrix metalloproteinases inhibitor (MMPIs). |
University of Florence |
| 27825552 |
152 |
Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. |
Takeda Pharmaceutical |
| 27452283 |
241 |
Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. |
Jadavpur University |
| 26653735 |
81 |
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis. |
Pfizer |
| 26753813 |
22 |
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid. |
University of Minnesota |
| 26314922 |
2 |
Imidazopyridines as a source of biological activity and their pharmacological potentials-Infrared and Raman spectroscopic evidence of their content in pharmaceuticals and plant materials. |
Wroclaw University of Economics |
| 25438884 |
11 |
A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹8F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging. |
University Medical Center Groningen |
| 25265401 |
38 |
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors. |
Universidad Ceu San Pablo |
| 24074025 |
3 |
Investigating the selectivity of metalloenzyme inhibitors. |
University of California San Diego |
| 24044937 |
59 |
Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group. |
University of Lille |
| 23810497 |
51 |
Hydantoin based inhibitors of MMP13--discovery of AZD6605. |
Astrazeneca |
| 24900710 |
25 |
Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold. |
University of Florence |
| 23353736 |
41 |
Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1). |
Second Military Medical University |
| 23287054 |
46 |
Sulphonamides: Deserving class as MMP inhibitors? |
Indian Institute of Technology (Bhu) |
| 23458498 |
24 |
Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography. |
Universit£ |
| 23343195 |
5 |
Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. |
Cea |
| 17275314 |
701 |
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs. |
Pomona College |
| 21669521 |
44 |
Selective non zinc binding inhibitors of MMP13. |
Astrazeneca |
| 24900526 |
3 |
Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. |
TBA |
| 21413800 |
56 |
A one-pot synthesis and biological activity of ageladine A and analogues. |
Macquarie University |
| 22658537 |
76 |
Natural products as a gold mine for selective matrix metalloproteinases inhibitors. |
East China University of Science and Technology |
| 22175799 |
22 |
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis. |
Alantos Pharmaceuticals |
| 22342144 |
72 |
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain. |
Panthera Biopharma |
| 21141896 |
2 |
Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase. |
P. Angeletti S.P.A. (Merck Research Laboratories) |
| 19715320 |
87 |
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. |
University of Florida |
| 18257543 |
16 |
Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. |
The Hebrew University of Jerusalem |
| 18251495 |
69 |
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. |
Pfizer |
| 18061445 |
103 |
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Research and Development |
| 18029173 |
316 |
Synthesis and evaluation of novel heterocyclic MMP inhibitors. |
North Dakota State University |
| 10882358 |
62 |
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. |
F. Hoffmann-La Roche |
| 15177439 |
96 |
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1. |
Pfizer |
| 12824028 |
75 |
Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3. |
Pfizer |
| 22386984 |
67 |
In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors. |
Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl) |
| 22175825 |
19 |
Potent inhibitors of LpxC for the treatment of Gram-negative infections. |
Pfizer |
| 22153941 |
140 |
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. |
Astrazeneca |
| 22017539 |
75 |
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. |
Boehringer Ingelheim Pharmaceuticals |
| 22017477 |
35 |
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases. |
Instituto Superior T£Cnico |
| 22153340 |
37 |
Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). |
Pfizer |
| 21344906 |
54 |
Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. |
The University of Tokyo |
| 21111619 |
9 |
Thiophene and bioisostere derivatives as new MMP12 inhibitors. |
Evotec Oai |
| 20965620 |
50 |
Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs). |
Protera |
| 20022498 |
71 |
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors. |
Schering-Plough Research Institute |
| 20005097 |
58 |
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis. |
Pfizer |
| 19665375 |
24 |
Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product. |
Kyorin Pharmaceutical |
| 19703773 |
63 |
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. |
Gsk Medicines Research Centre |
| 19775099 |
184 |
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors. |
Universit£ |
| 19725580 |
93 |
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma. |
Wyeth Research |
| 18974001 |
72 |
N-((8-hydroxy-5-substituted-quinolin-7-yl)(phenyl)methyl)-2-phenyloxy/amino-acetamide inhibitors of ADAMTS-5 (Aggrecanase-2). |
Wyeth Research |
| 18790648 |
317 |
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. |
University of Athens |
| 18494455 |
6 |
Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. |
Uppsala University |
| 17623656 |
34 |
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. |
Pfizer |
| 17583333 |
4 |
Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. |
Università |
| 17576061 |
132 |
Synthesis and structure-activity relationship of a novel, non-hydroxamate series of TNF-alpha converting enzyme inhibitors. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17574851 |
10 |
Synthesis and matrix metalloproteinase (MMP)-12 inhibitory activity of ageladine A and its analogs. |
Kyorin Pharmaceutical |
| 17368021 |
55 |
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17027261 |
153 |
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 16420030 |
38 |
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. |
Chinese Academy of Sciences |
| 16002291 |
24 |
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. |
Pfizer |
| 15780611 |
74 |
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. |
Pfizer |
| 15341955 |
52 |
Synthesis and evaluation of novel oxazoline MMP inhibitors. |
North Dakota State University |
| 15324896 |
71 |
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase. |
Pfizer |
| 14684295 |
109 |
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. |
Chinese Academy of Sciences |
| 12877587 |
6 |
Development of a water-soluble matrix metalloproteinase inhibitor as an intra-arterial infusion drug for prevention of restenosis after angioplasty. |
National Cardiovascular Center Research Institute |
| 11585440 |
76 |
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release. |
Dupont Pharmaceuticals |
| 11563922 |
147 |
Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. |
UniversitäT Bielefeld |
| 11384231 |
26 |
2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors. |
F. Hoffmann-La Roche |
| 30688452 |
94 |
Synthesis and Structural/Functional Characterization of Selective M14 Metallocarboxypeptidase Inhibitors Based on Phosphinic Pseudopeptide Scaffold: Implications on the Design of Specific Optical Probes. |
Universitat Aut£Noma De Barcelona |
| 30682248 |
15 |
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). |
School of Pharmaceutical Sciences & The Fifth Affiliated Hospital |
| 30846252 |
23 |
Recent developments in the synthesis and applications of phosphinic peptide analogs. |
Wroclaw University of Technology |
| 30429099 |
25 |
Matrix metalloproteinase-12 inhibitors: synthesis, structure-activity relationships and intestinal absorption of novel sugar-based biphenylsulfonamide carboxylates. |
University of Pisa |
| 30034610 |
35 |
Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1. |
Glaxosmithkline Pharmaceuticals |
| 29727184 |
56 |
Development of Thioaryl-Based Matrix Metalloproteinase-12 Inhibitors with Alternative Zinc-Binding Groups: Synthesis, Potentiometric, NMR, and Crystallographic Studies. |
Universit£ |
| 28818461 |
67 |
Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis. |
Nestl� |
| 29191557 |
10 |
Synthesis of radioiodinated probes targeted toward matrix metalloproteinase-12. |
Kobe Pharmaceutical University |
| 30249495 |
241 |
Development of matrix metalloproteinase-13 inhibitors - A structure-activity/structure-property relationship study. |
Graz University of Technology |
| 30034605 |
15 |
In Search of Selectivity in Inhibition of ADAM10. |
University of Notre Dame |
| 29456802 |
4 |
HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes. |
University of California-Riverside |
| 29028530 |
48 |
A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line. |
Jadavpur University |
| 29048889 |
7 |
Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX). |
University of Florence |
| 28653849 |
67 |
Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors. |
Scripps Florida |
| 21524149 |
13 |
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands. |
Suven Life Sciences |
| 8632342 |
110 |
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. |
Eli Lilly |
| 8358562 |
29 |
Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. |
Glaxo Group Research |
| 7651361 |
32 |
Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain. |
Georgetown University |
| 7518496 |
9 |
Cloning and expression of a 5-hydroxytryptamine7 receptor positively coupled to adenylyl cyclase. |
Syntex Discovery Research |
Search and Browse
